Dysphania ambrosioides as a Source of Antioxidant Candidates for Benign Prostatic Hyperplasia (BPH) and Prostatitis: A Critical Review and In Silico Prioritisation
Scientia Pharmaceutica · 13.11.2025 · 93 (4) · 57
DOI: 10.3390/scipharm93040057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 13.11.2025. Verfasst von Enrique Jiménez-Ferrer und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Benign prostatic hyperplasia (BPH) and prostatitis are multifactorial urological disorders associated with chronic inflammation, oxidative stress, and androgenic imbalance. Dysphania ambrosioides (L.) Mosyakin & Clemants contains flavonoids and phenolic acids with well-recognised antioxidant and anti-inflammatory properties; however, its potential activity against the molecular targets of these prostatic disorders has not been systematically evaluated. A comparative quantitative analysis was performed using studies published between 2005 and 2025 that reported antioxidant activity (DPPH assay, IC50 in µg/mL) of D. ambrosioides extracts. Metabolites from extracts with IC50 values below the global mean (398.410 ± 81.810 µg/mL; n = 35) were selected for in silico prioritisation using OSIRIS, PASS, and ProTox 3.0, followed by molecular docking (CB-Dock2) against AR, 5AR2, COX-2, NLRP3, and α1A receptors. Luteolin and rosmarinic acid showed favourable binding energies (−9.5 to −7.7 kcal/mol) comparable in magnitude to reference drugs (finasteride −13.4, celecoxib −11.4, tamsulosin −7.3 kcal/mol). These metabolites, exhibited affinity for androgenic, inflammatory, and adrenergic targets, suggesting their potential to modulate key mechanisms underlying both BPH and prostatitis. This study integrates, for the first time, a quantitative assessment of antioxidant activity with a multitarget in silico analysis of D. ambrosioides, prioritising luteolin and rosmarinic acid as natural candidates with potential antioxidant, anti-inflammatory, and antiandrogenic properties relevant to prostatic health.
Zitieren
APA
Jiménez-Ferrer, E., Abarca-Salgado, T., Vargas-Radilla, A., Flores-Melgar, J. D. J., & Abarca-Vargas, R. (2025). Dysphania ambrosioides as a Source of Antioxidant Candidates for Benign Prostatic Hyperplasia (BPH) and Prostatitis: A Critical Review and In Silico Prioritisation. Scientia Pharmaceutica, 93(4), 57. https://doi.org/10.3390/scipharm93040057
Vancouver
Jiménez-Ferrer E, Abarca-Salgado T, Vargas-Radilla A, Flores-Melgar JDJ, Abarca-Vargas R. Dysphania ambrosioides as a Source of Antioxidant Candidates for Benign Prostatic Hyperplasia (BPH) and Prostatitis: A Critical Review and In Silico Prioritisation. Scientia Pharmaceutica. 2025;93(4):57. doi:10.3390/scipharm93040057
BibTeX
@article{JimnezFerrer2025,
author = {Jiménez-Ferrer, Enrique and Abarca-Salgado, Tania and Vargas-Radilla, Azamar and Flores-Melgar, José de Jesús and Abarca-Vargas, Rodolfo},
title = {Dysphania ambrosioides as a Source of Antioxidant Candidates for Benign Prostatic Hyperplasia (BPH) and Prostatitis: A Critical Review and In Silico Prioritisation},
journal = {Scientia Pharmaceutica},
year = {2025},
volume = {93},
number = {4},
pages = {57},
doi = {10.3390/scipharm93040057}
}
EUVIMED